MPP is committed to achieving the highest standards of ethics, accountability and transparency.
As the Medicines Patent Pool’s role is to improve access to high-quality, affordable, essential medicines in low- and middle-income countries, we hold ourselves to the highest standards of ethics, accountability and transparency.
MPP’s Governance Board, with inputs from the Expert Advisory Group and the Scientific Advisory Panel, and the Community Advisory Panel defines MPP’s policies, reviews and approves MPP’s licensing agreements.
All MPP staff, members of its Governance Board, Expert Advisory Group, Scientific Advisory Panel and Community Advisory Panel must comply with these policies:
MPP is committed to ensuring full compliance with obligations under its licence agreements with licensors. A core part of these obligations centres around monitoring the activities of its sublicensees and taking prompt action to identify and remedy any breaches. These guidelines are intended to provide guidance on the principles and procedures that apply in the event of a suspected contractual breach by an MPP licensee.
Access the MPP guidelines for handling breaches of sublicence agreements
There is no tolerance for acts of wrongdoing within the organisation or in any project in which MPP is involved. Anyone can access MPP’s ethics portal anonymously if they want to report any concern they may have.
Access MPP’s ethics portal
The Medicines Patent Pool has joined the EPiHC initiative as a signatory, marking our commitment to the highest standard for ethical decision making and behaviour.
Click Here to Read More
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.